Nanoconjugated long non-coding RNA MEG3 as a new therapeutic approach for Hepatocellular carcinoma
Background: Hepatocellular carcinoma (HCC) is an aggressive human cancer with a poor prognosis. Long non-coding RNAs (lncRNA) have multiple functions: epigenomic regulation, gene transcription, protein-coding gene translation, and genome defense. The involvement of lncRNAs in therapy offers a vast s...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-04-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844023024957 |
| _version_ | 1827957281901248512 |
|---|---|
| author | Mohamed Elzallat Marwa Hassan Nabila Elkramani Tarek Aboushousha Ahmed AbdelLatif Noha Helal Hoda Abu-Taleb Eman El-Ahwany |
| author_facet | Mohamed Elzallat Marwa Hassan Nabila Elkramani Tarek Aboushousha Ahmed AbdelLatif Noha Helal Hoda Abu-Taleb Eman El-Ahwany |
| author_sort | Mohamed Elzallat |
| collection | DOAJ |
| description | Background: Hepatocellular carcinoma (HCC) is an aggressive human cancer with a poor prognosis. Long non-coding RNAs (lncRNA) have multiple functions: epigenomic regulation, gene transcription, protein-coding gene translation, and genome defense. The involvement of lncRNAs in therapy offers a vast step in cancer treatment. Objective: In the current study, a novel therapeutic regimen using polymer nanoparticle-mediated delivery of lncRNA was designed to control the progression of hepatocarcinogenesis. Methods: One hundred mice were divided into 5 groups. The first group served as a normal-control group and was injected with saline, whereas the pathological-control group (the second group) was injected with N-Nitrosodiethylamine (DEN) weekly for 16 weeks. Group 3, Group 4, and Group 5 were injected intrahepatically with polymer nanoparticles (NPs) alone, lncRNA MEG3 alone, and conjugated NPs, respectively, once/week for four weeks starting on the 12th week after DEN injection. After 16 weeks, animals were euthanized, and liver specimens and blood samples were collected for pathological, molecular, and biochemical assessment. Results: Compared to the pathological-control group, nanoconjugates lncRNA MEG3 demonstrated a significant improvement in histopathology and tumour-associated biomarkers. Furthermore, the expression of the SENP1 and PCNA was downregulated. Conclusion: MEG3 conjugated nanoparticles can be considered a novel therapeutic regimen for HCC. |
| first_indexed | 2024-04-09T15:16:48Z |
| format | Article |
| id | doaj.art-17190c9c869647c9a98ec66b93a9a53d |
| institution | Directory Open Access Journal |
| issn | 2405-8440 |
| language | English |
| last_indexed | 2024-04-09T15:16:48Z |
| publishDate | 2023-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj.art-17190c9c869647c9a98ec66b93a9a53d2023-04-29T14:56:04ZengElsevierHeliyon2405-84402023-04-0194e15288Nanoconjugated long non-coding RNA MEG3 as a new therapeutic approach for Hepatocellular carcinomaMohamed Elzallat0Marwa Hassan1Nabila Elkramani2Tarek Aboushousha3Ahmed AbdelLatif4Noha Helal5Hoda Abu-Taleb6Eman El-Ahwany7Immunology Department, Theodor Bilharz Research Institute, Giza, Egypt; Corresponding author.Immunology Department, Theodor Bilharz Research Institute, Giza, EgyptBiotechnology Program and Biology Department, School of Science and Engineering, American University in Cairo, Cairo, EgyptPathology Department, Theodor Bilharz Research Institute, Giza, EgyptBiotechnology Program and Biology Department, School of Science and Engineering, American University in Cairo, Cairo, Egypt; Corresponding author.Pathology Department, Theodor Bilharz Research Institute, Giza, EgyptEnviromental Research Department, Theodor Bilharz Research Institute, Giza, EgyptImmunology Department, Theodor Bilharz Research Institute, Giza, EgyptBackground: Hepatocellular carcinoma (HCC) is an aggressive human cancer with a poor prognosis. Long non-coding RNAs (lncRNA) have multiple functions: epigenomic regulation, gene transcription, protein-coding gene translation, and genome defense. The involvement of lncRNAs in therapy offers a vast step in cancer treatment. Objective: In the current study, a novel therapeutic regimen using polymer nanoparticle-mediated delivery of lncRNA was designed to control the progression of hepatocarcinogenesis. Methods: One hundred mice were divided into 5 groups. The first group served as a normal-control group and was injected with saline, whereas the pathological-control group (the second group) was injected with N-Nitrosodiethylamine (DEN) weekly for 16 weeks. Group 3, Group 4, and Group 5 were injected intrahepatically with polymer nanoparticles (NPs) alone, lncRNA MEG3 alone, and conjugated NPs, respectively, once/week for four weeks starting on the 12th week after DEN injection. After 16 weeks, animals were euthanized, and liver specimens and blood samples were collected for pathological, molecular, and biochemical assessment. Results: Compared to the pathological-control group, nanoconjugates lncRNA MEG3 demonstrated a significant improvement in histopathology and tumour-associated biomarkers. Furthermore, the expression of the SENP1 and PCNA was downregulated. Conclusion: MEG3 conjugated nanoparticles can be considered a novel therapeutic regimen for HCC.http://www.sciencedirect.com/science/article/pii/S2405844023024957LncRNAsMEG3HCCTherapyPolymer nanoparticles |
| spellingShingle | Mohamed Elzallat Marwa Hassan Nabila Elkramani Tarek Aboushousha Ahmed AbdelLatif Noha Helal Hoda Abu-Taleb Eman El-Ahwany Nanoconjugated long non-coding RNA MEG3 as a new therapeutic approach for Hepatocellular carcinoma Heliyon LncRNAs MEG3 HCC Therapy Polymer nanoparticles |
| title | Nanoconjugated long non-coding RNA MEG3 as a new therapeutic approach for Hepatocellular carcinoma |
| title_full | Nanoconjugated long non-coding RNA MEG3 as a new therapeutic approach for Hepatocellular carcinoma |
| title_fullStr | Nanoconjugated long non-coding RNA MEG3 as a new therapeutic approach for Hepatocellular carcinoma |
| title_full_unstemmed | Nanoconjugated long non-coding RNA MEG3 as a new therapeutic approach for Hepatocellular carcinoma |
| title_short | Nanoconjugated long non-coding RNA MEG3 as a new therapeutic approach for Hepatocellular carcinoma |
| title_sort | nanoconjugated long non coding rna meg3 as a new therapeutic approach for hepatocellular carcinoma |
| topic | LncRNAs MEG3 HCC Therapy Polymer nanoparticles |
| url | http://www.sciencedirect.com/science/article/pii/S2405844023024957 |
| work_keys_str_mv | AT mohamedelzallat nanoconjugatedlongnoncodingrnameg3asanewtherapeuticapproachforhepatocellularcarcinoma AT marwahassan nanoconjugatedlongnoncodingrnameg3asanewtherapeuticapproachforhepatocellularcarcinoma AT nabilaelkramani nanoconjugatedlongnoncodingrnameg3asanewtherapeuticapproachforhepatocellularcarcinoma AT tarekaboushousha nanoconjugatedlongnoncodingrnameg3asanewtherapeuticapproachforhepatocellularcarcinoma AT ahmedabdellatif nanoconjugatedlongnoncodingrnameg3asanewtherapeuticapproachforhepatocellularcarcinoma AT nohahelal nanoconjugatedlongnoncodingrnameg3asanewtherapeuticapproachforhepatocellularcarcinoma AT hodaabutaleb nanoconjugatedlongnoncodingrnameg3asanewtherapeuticapproachforhepatocellularcarcinoma AT emanelahwany nanoconjugatedlongnoncodingrnameg3asanewtherapeuticapproachforhepatocellularcarcinoma |